ABSTRACT
Objective Childhood trauma has been implicated as a risk factor for the aetiology of psychogenic non-epileptic seizures (PNES). Relatively little attention has been paid to whether profiles of specific trauma types differ between patients with epilepsy and PNES. Investigating childhood trauma profiles in these patient groups may identify psychological vulnerabilities the predispose to developing PNES, and aid early diagnoses, prevention, and treatment.
Methods Data were collected from two cohorts (nRetrospective=203; nProspective=209) admitted to video-EEG monitoring units in Melbourne Australia. The Childhood Trauma Questionnaire domain score differences between patient groups were investigated using standardised effect sizes and general linear mixed-effects models (GLMMs). Receiver operating characteristic curves were used to investigate classification accuracy.
Results In the retrospective cohort, patients diagnosed with PNES reported greater childhood emotional abuse, emotional neglect, physical abuse, sexual abuse, and physical neglect relative to epilepsy patients. These differences were replicated in the prospective cohort, except for physical abuse. GLMMs revealed significant main effects for group in both cohorts, but no evidence for any group by domain interactions. Reported sexual abuse showed the best screening performance of PNES, although no psychometric scores were adequate as isolated measures.
Conclusions Patients with PNES report greater frequency of childhood trauma than patients with epilepsy. This effect appears to hold across all trauma types, with no strong evidence emerging for a particular trauma type that is more prevalent in PNES. From a practical perspective, inquiring regarding a history of sexual abuse shows the most promise as a screening measure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from The Melbourne Health, The Alfred Health Research and Ethics Committee, and The University of Melbourne Human Ethics Advisory Group.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Conducted statistical analysis
Study funding: None to declare.
Disclosures: Ms Yang reports no disclosures.
Prof Terence O’Brien’s institution has received grant funding from the NHMRC (Investigator Grant APP1176426), MRFF, NIH and US DOD. His institution has also received research and/or consulting fees from Industry, including Eisai, UCB, Biogen, Supernus, Praxis Pharmaceuticals, ES Therapeutics and Epidarex.
Prof Kwan is supported by a Practitioner Fellowship (MRF1136427) from the Medical Research Future Fund.
Dr Rayner is supported in part by the Australian Epilepsy Research Fund and has received funding from the NHMRC (Investigator grant APP2008737). This funding is unrelated to this study.
A/Prof Charles Malpas has received conference travel support and/or speaker Merck and has received research support from the National Health and Medical Research Council, Multiple Sclerosis Research Australia, The University of Melbourne, The Royal Melbourne Hospital Neuroscience Foundation, and Dementia Australia.
Data Accessibility Statement: De-identified data may be accessed by contacting the corresponding author.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.